Innovent Biologics (HK:1801) has released an update.
Innovent Biologics has announced the acceptance of its second New Drug Application for mazdutide by China’s National Medical Products Administration, signaling a potential breakthrough for type 2 diabetes treatment in China. The drug, which has shown promising results in Phase 3 trials, could offer significant benefits in glycemic control, weight reduction, and cardiovascular and renal health for China’s large diabetic population. This development positions Innovent Biologics as a key player in addressing the growing health challenge of diabetes in the country.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.
